55604-95-0

Basic information

• Product Name: Acetamide, N-[2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-2-oxo-1-(phenylmethyl)ethyl]-, (S)-
• Synonyms: (S)-2-Acetylamino-3-phenyl-propionic acid 2,5-dioxo-pyrrolidin-1-yl ester;N-acetyl-L-phenylalanine N-hydroxysuccinimide ester
• CAS NO: 55604-95-0
• Molecular Formula: C15H16N2O5
• Molecular Weight: 304.302
• Mol File: 55604-95-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Acetamide, N-[2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-2-oxo-1-(phenylmethyl)ethyl]-, (S)-(CAS DataBase Reference)
• NIST Chemistry Reference: Acetamide, N-[2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-2-oxo-1-(phenylmethyl)ethyl]-, (S)-(55604-95-0)
• EPA Substance Registry System: Acetamide, N-[2-[(2,5-dioxo-1-pyrrolidinyl)oxy]-2-oxo-1-(phenylmethyl)ethyl]-, (S)-(55604-95-0)

Safety Data

• Hazardous Substances Data: 55604-95-0(Hazardous Substances Data)

Upstream product

• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 5469-44-3 2-methyl-4-benzyl-4H-oxazolin-5-one 
• 2018-61-3 (S)-2-acetylamino-3-phenylpropanoic acid 

Downstream Products

• 1349173-02-9 Ac-Phe-SH 
• 1349173-05-2 Ac-Phe-Thr-NHBn 
• 1349173-03-0 C₂₂H₂₅N₃O₃ 
• 10030-31-6 (S)-2-((S)-2-acetamido-3-phenylpropanamido)-3-phenylpropanoic acid 
• 372965-52-1 ethyl 4-acetylamino-2-cyano-3-hydroxy-5-phenylpent-2-enoate 
• 61884-22-8 SS-acetylphenylalanine α-phenylethylamide 
• 102153-08-2 Ac-Phe-Phe-Sta-Ala-sta-OCH₃ 
• 102153-19-5 Ac-Phe-Nva-Sta-Ala-Sta-OCH₃ 

Relevant articles and documents

Aziridine-mediated ligation and site-specific modification of unprotected peptides

A synthesis of aziridine-containing peptides via the Cu(II)-promoted coupling of unprotected peptide thioacids and N-H aziridine-2-carbonyl peptides is reported. The unique reactivity of the resulting N-acylated aziridine-2-carbonyl peptides facilitates t

Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin

A series of lysosomal protease-sensitive peptides attached to doxorubicin (DOX) was prepared as model substrates for internalizing anticancer immunoconjugates and potential antimetastasis prodrugs. Rates of cathepsin B-mediated release of free drug was measured for each, and human plasma stabilities for representative examples.